Third Rock, Access And Clal Invest In Cancer Therapy

October 1, 2015 | The American venture capital firm Third Rock Ventures, Len Blavatnik’s Access Industries and a daughter company of Clal Biotechnology will invest $55 million in  Neon Therapeutics. The investment will reportedly be used to help Neon Therapeutics complete its cancer immunotherapy. Clal Biotechnoloigy was founded in 1998 and is based out of Ramat Gan, Israel.